Literature DB >> 17124061

Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes.

James W Vardiman1.   

Abstract

Although the diagnosis and classification of most cases of the myelodysplastic syndromes (MDS) is usually accomplished without difficulty, a minority of cases may pose diagnostic problems. In many cases the diagnostic dilemma can be solved by adhering to basic guidelines recommended for evaluation of patients suspected of having MDS, and in particular to the quality of the blood and bone marrow specimens submitted for morphologic, immunophenotypic and genetic studies. In other cases, such as patients who have hypocellular MDS or MDS with fibrosis, the criteria for making a diagnosis may be difficult if not impossible to apply, and in still others the diagnostic uncertainty is because the minimal criteria necessary to establish the diagnosis of MDS are not always clearly stated. In this review, some of these diagnostic problems are addressed and some general guidelines for resolving them are suggested. In addition, data are presented that illustrate that the WHO classification offers a valuable tool in the diagnosis and classification of MDS.

Entities:  

Mesh:

Year:  2006        PMID: 17124061     DOI: 10.1182/asheducation-2006.1.199

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  13 in total

1.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 3.  New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.

Authors:  Zuzana Tothova; David P Steensma; Benjamin L Ebert
Journal:  Clin Cancer Res       Date:  2013-01-17       Impact factor: 12.531

4.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Authors:  M G Della Porta; E Travaglino; E Boveri; M Ponzoni; L Malcovati; E Papaemmanuil; G M Rigolin; C Pascutto; G Croci; U Gianelli; R Milani; I Ambaglio; C Elena; M Ubezio; M C Da Via'; E Bono; D Pietra; F Quaglia; R Bastia; V Ferretti; A Cuneo; E Morra; P J Campbell; A Orazi; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

5.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

6.  Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes.

Authors:  Nobutaka Kawai; Akira Matsuda; Itsuro Jinnai; Takaya Ichimura; Hidekazu Kayano; Daisuke Okamura; Maho Ishikawa; Tomoya Maeda; Tomoko Hata; Yasushi Miyazaki; Norio Asou; Masami Bessho; Masao Tomonaga
Journal:  Int J Hematol       Date:  2015-11-25       Impact factor: 2.490

7.  Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

Authors:  David P Steensma; Medrdad Abedi; Rafael Bejar; Christopher R Cogle; Kathryn Foucar; Guillermo Garcia-Manero; Tracy I George; David Grinblatt; Rami Komrokji; Xiaomei Ma; Jaroslaw Maciejewski; Daniel A Pollyea; Michael R Savona; Bart Scott; Mikkael A Sekeres; Michael A Thompson; Arlene S Swern; Melissa Nifenecker; Mary M Sugrue; Harry Erba
Journal:  BMC Cancer       Date:  2016-08-19       Impact factor: 4.430

8.  Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study.

Authors:  Flávia Sacilotto Donaires; Felipe Martelli; Raquel de Melo Alves-Paiva; Silvia Maria Meira Magalhães; Ronald Feitosa Pinheiro; Rodrigo Tocantins Calado
Journal:  Rev Bras Hematol Hemoter       Date:  2016-07-04

9.  Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems.

Authors:  Özlen Bektaş; Ayşegül Üner; Eylem Eliaçık; Burak Uz; Ayşe Işık; Sezgin Etgül; Süreyya Bozkurt; İbrahim Celalettin Haznedaroğlu; Hakan Göker; Nilgün Sayınalp; Salih Aksu; Haluk Demiroğlu; Osman İlhami Özcebe; Yahya Büyükaşık
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

Review 10.  Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog.

Authors:  Ethan A Natelson; David Pyatt
Journal:  Adv Hematol       Date:  2013-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.